Pazocent 200 mg (Tablet)
Unit Price: ৳ 280.00 (1 x 10: ৳ 2,800.00)
Strip Price: ৳ 2,800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Pazopanib hydrochloride |
| Company | Incepta pharmaceuticals ltd |
Indications
- Treatment of advanced renal cell carcinoma (RCC)
- Treatment of advanced soft tissue sarcoma (STS)
Pharmacology
- Multi-tyrosine kinase inhibitor
- Inhibition of VEGFR, PDGFR, and FGFR
- Absorption median time: 2 to 4 hours
- Protein binding >99%
- Metabolized by CYP3A4
- Mean half-life: 30.9 hours
Dosage & Administration
- Recommended starting dose: 800 mg orally
- Once daily without food
- Tablets should not be crushed
- Missed dose guidance
Interaction
- Metabolism mediated primarily by CYP3A4
- Inhibitors and inducers of CYP3A4 may alter metabolism
- Coadministration with strong CYP3A4 inhibitors to be avoided
- Avoid chronic use of strong CYP3A4 inducers
- Substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)
- Weak inhibitor of CYP3A4, CYP2C8, and CYP2D6
Contraindications
- Known hypersensitivity to Pazopanib or any other components
Side Effects
- Hepatic Toxicity
- QT Prolongation and Torsades de Pointes
- Cardiac Dysfunction
- Hemorrhagic Events
- Hypertension
- Proteinuria
- Infection
Pregnancy & Lactation
- Can cause fetal harm
- No data on presence in human milk
- Lactating women advised not to breastfeed
Precautions & Warnings
- Hepatotoxicity observed, especially in patients over 65
- QT interval prolongation and relevant pre-existing cardiac disease
Use in Special Populations
- Females advised to use effective contraception during treatment
- Males advised to use condoms during treatment
Overdose Effects
- Dose-limiting toxicity observed at 2000 mg daily
- No specific antidote for overdosage
- General supportive measures recommended
Storage Conditions
- Store below 30°C
- Cool and dry place
- Keep out of reach of children